- In a report published Tuesday, Evercore ISI analyst Mark Schoenebaum enumerated the upcoming catalysts for Biogen Idec Inc BIIB. These include:
Quarterly calls: Tecfidera sales number
March 2015 - ADPD Conference: BIIB-037 Ph 1b mild / prodromal alzheimer's detailed data
April 2015 (AAN Conference): Detailed LINGO (Optic Neuritis) Phase 2 data
1H15: Alprolix Kids B-Long Phase 3 data readout
2H15: Tysabri Phase 3 SPMS readout
2H15: Neublastin - Ph 2 Painful Lumbar Radiculopathy readout
2015: Tysabri Phase 2 acute ischemic stroke data
2015: Gazyva DLBCL Phase 3 data
2015: STX-100 - Ph2a IPF (n=32)
2016: Anti-LINGO - Ph 2 MS trial (SYNERGY)
Although interim results would be declared in 2H15, they could remain blinded, not offering any data, the analyst added.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.